A 2024 academic assessment of Australia's prescription model for vapes and an alternative
Source material dated October 2024 · Regulation and law
Overview
The source was a 2024 opinion article on drug policy. It reviewed Australia's approach to vaping and argued that the prescription model, together with a ban on retail sale of nicotine vapes, had not met its aims. It proposed replacing that model with regulated retail sales. The summary reports the commentary's reasoning, which is one position in a continuing public health dispute.
Two policy philosophies
The source described a split among public health bodies. One approach in England promoted vapes as a quitting aid and a less harmful alternative to cigarettes, and allowed retail sale. The other, adopted in Australia from 2016, put the prevention of adolescent uptake first and made nicotine vapes available only as prescription medicines. The source said policymakers had been sceptical that vaping helps people quit and had expected that adult smokers might later reach approved products through the medicines regulator.
How the policy had performed, according to the source
The source argued that youth vaping had not been prevented and that talk of an epidemic relied on lifetime use figures of 35 per cent while giving less attention to much lower figures for past-month and past-week use. It reported that the regulator had approved no vapes for quitting and that by 2023 fewer than 10 per cent of an estimated 1.8 million users held a prescription. It attributed this to easy access to illicit supply and to reluctance among medical practitioners. It also said illegal vape sales had joined an existing illicit tobacco market driven by high tobacco taxes.
The proposed alternative
The source said the choice was not limited to prescriptions or unregulated sale. It suggested plain packaging, limits on promotion, licensed retailers, enforced age limits, and recorded sales, citing recent United States experience in reducing youth vaping. It also proposed a public messaging campaign covering relative risk.
Context and limits
The article described policy as it stood in 2024, including a proposed shift to pharmacy supply, and the rules have since been the subject of further change. The statistics are the author's selection from several surveys. Supporters of the prescription model dispute the reading of the youth figures and the claim that it failed.
Based on a 2024 opinion article in an Australian public policy publication.
Related summaries
- A 2024 survey of pharmacy availability under Australia's new vape rules
- Pharmacy-only vape supply: a 2024 view on the reform bill changes
- Australia's 2024 vape rules at the start of July: a record of the pharmacy-based model
- Planned Australian vape rules as described in late 2023: prescriptions, flavours and imports